Commentary

Page 5

Recently published articles about Commentary

Functional Outcomes of an Antipsychotic in Schizophrenia: Generalizable or Specific Effect?

Commentary

Functional Outcomes of an Antipsychotic in Schizophrenia: Generalizable or Specific Effect?

March 1, 2022

This commentary takes a closer look at Correll and colleagues’ findings on functional outcomes with brexpiprazole.

Nina R. Schooler

Commentary

Response to the Opioid Crisis and the COVID-19 Pandemic

January 20, 2022

In this commentary, the authors discuss biological similarities of the opioid epidemic and the COVID-19 pandemic, as well as differences in response to the 2 public health crises.

Akshay P. Padala , Kerrie B. Wilson , Aparna Das

Commentary

Psychiatric Disorders and COVID-19 Outcomes

January 20, 2022

Patients with psychiatric disorders may be at greater risk of experiencing adverse outcomes from COVID-19. Read on to find out more.

Ramu Vadukapuram , Chintan Trivedi , Zeeshan Mansuri

Commentary

Classic Psychedelics and Self-Harm

January 18, 2022

This commentary discusses the article by Zeifman and colleagues on the role classic psychedelic agents may have in reducing risk of suicide.

Daniel H. Grossman , Peter S. Hendricks

Commentary

Ketamine and Cognitive Function in Depression

January 4, 2022

This commentary discusses the review by Vaccarino and colleagues of cognitive effects associated with ketamine treatment for major depressive disorder.

Joseph F. Goldberg

Commentary

Omicron (B.1.1.529) COVID-19 Variant

December 16, 2021

In this commentary, the authors discuss the new Omicron variant of COVID-19 as well as the potential mental health challenges that will likely unfold over the next year.

Ankit Jain , Taranjeet S. Jolly